Zymeworks
ZYME | NASDAQ
$26.45
+$0.21 (+0.80%)
At close: Nov 16, 2026, 4:00 PM ET
$26.45
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Zymeworks Company Profile
Company profile explainedCompany Profile
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
Key Executives
| Name | Position |
|---|---|
| Kenneth H. Galbraith | Chairman of the Board, Chief Executive Officer & President |
| Mark Hollywood | Executive VP & Chief Operating Officer |
| Bijal Desai | Senior Vice President of Finance |
| Diana Papove | Vice President of Corporate Communications |
| Kristin Stafford | Executive VP & CFO |
| Laura O'Connor | Senior VP & Chief Human Resources Officer |
| Lindsey Foulkes | Senior Vice President of Corporate Development & Strategy |
| Paul Moore | Chief Scientific Officer |
| Paul R. Schneider | Executive VP & General Counsel |
| Sabeen Mekan | Senior VP & Chief Medical Officer |
| Scott Platshon | Executive VP & Chief Business Officer |
| Shrinal Inamdar | Vice President of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 26, 2026 | ARS | Filing |
| Oct 26, 2026 | DEFA14A | Filing |
| Oct 26, 2026 | DEF 14A | Filing |
| Oct 23, 2026 | 8-K | Current Report |
| Oct 16, 2026 | PRE 14A | Filing |
| Oct 09, 2026 | 4 | Filing |
| Sep 23, 2026 | 8-K | Current Report |
| Aug 25, 2026 | 8-K | Current Report |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
Zymeworks
| Country | United States |
| IPO Date | Apr 28, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 231 |
| CEO | Kenneth H. Galbraith |
Contact Details
108 Patriot Drive Middletown,
Delaware 19709 United States
Stock Details
| Ticker Symbol | ZYME |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001937653 |
| CUSIP Number | 98985Y108 |
| ISIN Number | US98985Y1082 |
| SIC Code | 2834 |
Recent News
- 20 hours ago / globenewswire.comZymeworks Announces $200 Million Share Repurchase Authorization
- 7 days ago / zacks.comZymeworks Inc. (ZYME) Misses Q3 Earnings Estimates
- 7 days ago / globenewswire.comZymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results
- 19 days ago / zacks.comZymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings Growth
- 20 days ago / marketbeat.comZymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside
- 20 days ago / seekingalpha.comZymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates Transcript
- 24 days ago / globenewswire.comZymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
- 25 days ago / globenewswire.comZymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3
- 29 days ago / globenewswire.comZymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma
- 1 month ago / globenewswire.comZymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results
Add to Watchlist
Select watchlists to add or remove ZYME